SpinDiag
Freiburg
About SpinDiag
Spindiag provides an easy-to-use, compact, and automated point-of-care system for the broad, fast, and affordable detection of pathogens. It's first product is an automated SARS-CoV-2 test. Spindiag one can be operated with an easy to use and routine-compatible workflow by a nurse. Test results are directly transferred into the patient record. The patented centrifugal-microfluidic test system rapidly provides laboratory-grade PCR results directly from standard patient swab samples. SpinDiag works with your standard Copan ESwab® and allows culture confirmation or other lab tests without the necessity to take a second sample. The complete workflow is fully automated and suitable for operation by ward nurses. It features an ultrafast and highly-sensitive polymerase chain reaction (PCR).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: Less than $1M
- Total funding: $42.3M
- Funding stage: Early Stage Venture
- Last round: Debt Financing (Oct 2022)
- Website: spindiag.de
- Phone: [email protected]
Industries & Categories
Health Care, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/spindiag-11377 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.